Cited by 141Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsHormonal and reproductive studies

HRT for women with premature ovarian insufficiency: a comprehensive review

Open access
Webber, Lisa, Anderson, Richard A., Davies, Melanie, Janse, Femi, Vermeulen, Nathalie·2017·Human Reproduction Open

Abstract

BACKGROUND: Premature ovarian insufficiency (POI), often and misleadingly referred to as 'premature menopause', is defined as a loss of ovarian activity before the age of 40 years and is characterized by irregular or absent periods and reduced fertility. Symptoms include those associated with the natural menopause (night sweats and vaginal dryness), and with the long-term adverse effects of estrogen deficiency (osteoporosis and cardiovascular disease): the latter is believed to explain the shorter life expectancy associated with POI. OBJECTIVE AND RATIONALE: The objective of the current review was to collect all relevant studies supporting recommendations on the indications, treatment options, and risks of hormone replacement therapy (HRT) (estrogen, progestogens and androgens) for women with POI. SEARCH METHODS: The current review was written based on the best available evidence on the topic collected for the recently published ESHRE guideline on the management of women with POI. PUBMED/MEDLINE and the Cochrane library were searched in a stepwise approach. Relevant references were summarized in evidence tables, with assessment of the quality. OUTCOMES: HRT is strongly recommended for women with POI, mainly for vasomotor and genito-urinary symptom relief. In addition, HRT has been shown to have a role in bone protection and probably also in primary prevention of cardiovascular disease. There is little evidence on the optimal type, regimen and dose of HRT; patient preference for route and method of administration of each component of HRT must be considered when prescribing, as should contraceptive needs. In women with POI, physiological replacement of estrogen (and progesterone) is essential for their health, and the controversies that surround the use of HRT in postmenopausal women do not apply. LIMITATIONS REASONS FOR CAUTION: N/A. WIDER IMPLICATIONS: New areas of study on HRT for women with POI should focus on life expectancy, quality of life and neurological function. Furthermore, randomized controlled trials comparing transdermal estradiol with oral estrogens with regard to efficacy, patient satisfaction and side effects are urgently needed. STUDY FUNDING/COMPETING INTERESTS: The authors received no funding for the review. The costs for the development of the ESHRE guideline were covered by ESHRE. The authors have no conflicts of interest to disclose.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hropen/hox007

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 138 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. European Society of Human Reproduction and Embryology Guideline Group on POI External review report ‘Management of women with Premature Ovarian Insufficiency’. 2015.

Cited by

Sorted by citations

Authors
Webber, L., Anderson, R. A., Davies, M., Janse, F., & Vermeulen, N.
Affiliations
  • University College Hospital (GB)
  • MRC Centre for Reproductive Health (GB)
  • University Medical Center Utrecht (NL)
  • European Society of Human Reproduction and Embryology (BE)
Corresponding author
Webber, Lisa
Venue
Human Reproduction Open
Published
2017
Volume
2017
Issue
2
Pages
hox007-hox007
ISSN
2399-3529 (ISSN-L)
OpenAlex
W2735417387
Cited by
141
References
138
Citations by year
2026: 26 · 2025: 10 · 2024: 19 · 2023: 20 · 2022: 21 · 2021: 30 · 2020: 11 · 2019: 4
FWCI
0.60
Type
journal article
Language
en
Open access
Locations
  • Human Reproduction Open (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
Funders
European Society of Human Reproduction and Embryology
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
premature ovarian insufficiency, hormone replacement therapy, estrogen deficiency, vasomotor symptoms, genitourinary symptoms, bone protection, cardiovascular disease prevention, progestogens, androgens, transdermal estradiol, oral estrogen, ESHRE guidelines, life expectancy, quality of life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review